X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs BIOCON LTD - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES BIOCON LTD DIVIS LABORATORIES/
BIOCON LTD
 
P/E (TTM) x 18.1 36.6 49.6% View Chart
P/BV x 3.9 4.9 80.7% View Chart
Dividend Yield % 1.6 1.5 103.7%  

Financials

 DIVIS LABORATORIES   BIOCON LTD
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
BIOCON LTD
Mar-16
DIVIS LABORATORIES/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs2,484496 501.0%   
Low Rs918397 231.6%   
Sales per share (Unadj.) Rs142.3174.3 81.6%  
Earnings per share (Unadj.) Rs41.944.8 93.5%  
Cash flow per share (Unadj.) Rs46.356.9 81.4%  
Dividends per share (Unadj.) Rs10.005.00 200.0%  
Dividend yield (eoy) %0.61.1 52.5%  
Book value per share (Unadj.) Rs161.5202.8 79.6%  
Shares outstanding (eoy) m265.47200.00 132.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x12.02.6 467.1%   
Avg P/E ratio x40.610.0 407.9%  
P/CF ratio (eoy) x36.77.8 468.4%  
Price / Book Value ratio x10.52.2 478.7%  
Dividend payout %23.911.2 214.0%   
Avg Mkt Cap Rs m451,52589,220 506.1%   
No. of employees `0003.74.4 84.0%   
Total wages/salary Rs m3,6496,363 57.4%   
Avg. sales/employee Rs Th10,184.47,894.5 129.0%   
Avg. wages/employee Rs Th984.11,441.2 68.3%   
Avg. net profit/employee Rs Th2,998.52,029.7 147.7%   
INCOME DATA
Net Sales Rs m37,76434,854 108.3%  
Other income Rs m848845 100.4%   
Total revenues Rs m38,61235,699 108.2%   
Gross profit Rs m14,1388,200 172.4%  
Depreciation Rs m1,1822,423 48.8%   
Interest Rs m23102 22.7%   
Profit before tax Rs m13,7816,520 211.4%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m05,754 0.0%   
Tax Rs m2,6622,569 103.6%   
Profit after tax Rs m11,1198,961 124.1%  
Gross profit margin %37.423.5 159.1%  
Effective tax rate %19.339.4 49.0%   
Net profit margin %29.425.7 114.5%  
BALANCE SHEET DATA
Current assets Rs m30,94739,932 77.5%   
Current liabilities Rs m5,19516,276 31.9%   
Net working cap to sales %68.267.9 100.5%  
Current ratio x6.02.5 242.8%  
Inventory Days Days11754 218.0%  
Debtors Days Days8586 98.8%  
Net fixed assets Rs m17,02739,101 43.5%   
Share capital Rs m5311,000 53.1%   
"Free" reserves Rs m42,34138,591 109.7%   
Net worth Rs m42,87740,556 105.7%   
Long term debt Rs m520,724 0.0%   
Total assets Rs m49,68484,816 58.6%  
Interest coverage x595.064.9 916.5%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.80.4 185.0%   
Return on assets %22.410.7 209.9%  
Return on equity %25.922.1 117.4%  
Return on capital %32.219.0 169.6%  
Exports to sales %85.330.7 277.3%   
Imports to sales %22.920.4 112.4%   
Exports (fob) Rs m32,19810,717 300.4%   
Imports (cif) Rs m8,6547,105 121.8%   
Fx inflow Rs m32,27011,789 273.7%   
Fx outflow Rs m8,7758,393 104.5%   
Net fx Rs m23,4963,396 691.9%   
CASH FLOW
From Operations Rs m10,3795,264 197.2%  
From Investments Rs m-4,135-9,540 43.3%  
From Financial Activity Rs m-6,24110,867 -57.4%  
Net Cashflow Rs m36,591 0.1%  

Share Holding

Indian Promoters % 52.0 40.4 128.7%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 11.8 8.4 140.5%  
FIIs % 19.0 10.7 177.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 19.9 86.4%  
Shareholders   31,796 109,995 28.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SANOFI INDIA  TORRENT PHARMA  PLETHICO PHARMA  CIPLA  ABBOTT INDIA  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 18, 2017 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS